131 related articles for article (PubMed ID: 15342382)
1. Conditional deletion of Rb causes early stage prostate cancer.
Maddison LA; Sutherland BW; Barrios RJ; Greenberg NM
Cancer Res; 2004 Sep; 64(17):6018-25. PubMed ID: 15342382
[TBL] [Abstract][Full Text] [Related]
2. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.
Zhou Z; Flesken-Nikitin A; Corney DC; Wang W; Goodrich DW; Roy-Burman P; Nikitin AY
Cancer Res; 2006 Aug; 66(16):7889-98. PubMed ID: 16912162
[TBL] [Abstract][Full Text] [Related]
3. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue.
Wang Y; Hayward SW; Donjacour AA; Young P; Jacks T; Sage J; Dahiya R; Cardiff RD; Day ML; Cunha GR
Cancer Res; 2000 Nov; 60(21):6008-17. PubMed ID: 11085521
[TBL] [Abstract][Full Text] [Related]
4. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.
Sutherland BW; Knoblaugh SE; Kaplan-Lefko PJ; Wang F; Holzenberger M; Greenberg NM
Cancer Res; 2008 May; 68(9):3495-504. PubMed ID: 18451178
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells.
Davis JN; McCabe MT; Hayward SW; Park JM; Day ML
Cancer Res; 2005 May; 65(9):3633-42. PubMed ID: 15867358
[TBL] [Abstract][Full Text] [Related]
6. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
7. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer.
Lin SH; Pu YS
Semin Oncol; 1999 Apr; 26(2):227-33. PubMed ID: 10597733
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of Apc in the mouse prostate causes prostate carcinoma.
Bruxvoort KJ; Charbonneau HM; Giambernardi TA; Goolsby JC; Qian CN; Zylstra CR; Robinson DR; Roy-Burman P; Shaw AK; Buckner-Berghuis BD; Sigler RE; Resau JH; Sullivan R; Bushman W; Williams BO
Cancer Res; 2007 Mar; 67(6):2490-6. PubMed ID: 17363566
[TBL] [Abstract][Full Text] [Related]
9. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
[TBL] [Abstract][Full Text] [Related]
10. Alterations of p53 are common in early stage prostate cancer.
Downing SR; Russell PJ; Jackson P
Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
[TBL] [Abstract][Full Text] [Related]
11. Tumour suppressor genes in prostate cancer.
MacGrogan D; Bookstein R
Semin Cancer Biol; 1997 Feb; 8(1):11-9. PubMed ID: 9299577
[TBL] [Abstract][Full Text] [Related]
12. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
[TBL] [Abstract][Full Text] [Related]
13. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.
Sage J; Miller AL; Pérez-Mancera PA; Wysocki JM; Jacks T
Nature; 2003 Jul; 424(6945):223-8. PubMed ID: 12853964
[TBL] [Abstract][Full Text] [Related]
14. Earlier onset of melanotroph carcinogenesis in mice with inherited mutant paternal allele of the retinoblastoma gene.
Nikitin AY; Riley DJ; Lee WH
Cancer Res; 1997 Oct; 57(19):4274-8. PubMed ID: 9331088
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts.
Zhou Z; Flesken-Nikitin A; Nikitin AY
Cancer Res; 2007 Jun; 67(12):5683-90. PubMed ID: 17553900
[TBL] [Abstract][Full Text] [Related]
16. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
[TBL] [Abstract][Full Text] [Related]
17. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
Kasper S
J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647
[TBL] [Abstract][Full Text] [Related]
18. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
19. Autochthonous mouse models for prostate cancer: past, present and future.
Huss WJ; Maddison LA; Greenberg NM
Semin Cancer Biol; 2001 Jun; 11(3):245-60. PubMed ID: 11407949
[TBL] [Abstract][Full Text] [Related]
20. Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis.
Casanovas O; Hager JH; Chun MG; Hanahan D
Oncogene; 2005 Oct; 24(44):6597-604. PubMed ID: 16007165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
